Literature DB >> 11392886

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood.

D Jones1, N H Dang, M Duvic, L T Washington, Y O Huh.   

Abstract

We report flow cytometric characterization of surface CD26 expression in 271 peripheral blood samples from 154 patients evaluated for the presence of a T-cell lymphoproliferative disorder, primarily mycosis fungoides/Sézary syndrome (MF/SS). The presence of morphologically identifiable tumor cells on peripheral blood smears was the criterion for lymphomatous involvement. In 66 of 69 samples from 28 patients, we identified an abnormal CD26-/dim T-cell population that was distinct from the variable CD26 expression seen in normal peripheral blood T cells. This population was CD26- in 23 patients and weakly CD26+ in 5 patients. CD7 was more variably expressed in MF/SS tumor cells, allowing recognition of a distinct, quantifiable abnormal T-cell population in only 34 of 69 involved samples. An increased CD4/CD8 ratio and lower surface expression of CD4 in tumor cells also helped separate the CD26-/dim atypical population for quantification. In 35 blood samples from other types of T-cell tumors, tumor cells in 10 of 11 morphologically involved cases showed absent/dim CD26. Although capable of detecting abnormalities in most cases of MF/SS, CD7 expression does not provide as clear a separation of the neoplastic population and can be replaced by CD26 staining in routine peripheral blood flow cytometric screening of MF/SS patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11392886     DOI: 10.1309/U1Y6-J4AG-5M4M-7AYV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  30 in total

1.  The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.

Authors:  Enrico Scala; Damiano Abeni; Debora Pomponi; Maria Grazia Narducci; Giuseppe Alfonso Lombardo; Adriano Mari; Marina Frontani; Maria Cristina Picchio; Maria Antonietta Pilla; Elisabetta Caprini; Giandomenico Russo
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

2.  Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Authors:  Michael Nebozhyn; Andrey Loboda; Laszlo Kari; Alain H Rook; Eric C Vonderheid; Stuart Lessin; Carole Berger; Richard Edelson; Calen Nichols; Malik Yousef; Lalitha Gudipati; Meiling Shang; Michael K Showe; Louise C Showe
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

Review 3.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

4.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

5.  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Authors:  Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

6.  Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.

Authors:  Haipeng Shao; Constance M Yuan; Liqiang Xi; Mark Raffeld; John C Morris; John E Janik; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

Review 7.  Peripheral T and NK cell non-hodgkin lymphoma a challenge for diagnosis.

Authors:  Daniela Vasile; Ana-Maria Vladareanu; Horia Bumbea
Journal:  Maedica (Buchar)       Date:  2014-03

8.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

9.  CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.

Authors:  Nicolas Ortonne; Sabine Le Gouvello; Hicham Mansour; Catherine Poillet; Nadine Martin; Marie-Hélène Delfau-Larue; Karen Leroy; Jean-Pierre Farcet; Martine Bagot; Armand Bensussan
Journal:  J Invest Dermatol       Date:  2007-08-16       Impact factor: 8.551

10.  Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors.

Authors:  U Aytac; K Sato; T Yamochi; T Yamochi; K Ohnuma; G B Mills; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.